LV10051B - Method for producing of lyophilized yphosphamide - Google Patents

Method for producing of lyophilized yphosphamide Download PDF

Info

Publication number
LV10051B
LV10051B LVP-92-174A LV920174A LV10051B LV 10051 B LV10051 B LV 10051B LV 920174 A LV920174 A LV 920174A LV 10051 B LV10051 B LV 10051B
Authority
LV
Latvia
Prior art keywords
bis
die
und
der
ifosfamid
Prior art date
Application number
LVP-92-174A
Other languages
English (en)
Latvian (lv)
Other versions
LV10051A (lv
Inventor
Sauerbier Dieter
Damann Uwe-Peter
Isaac Otto
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of LV10051A publication Critical patent/LV10051A/xx
Publication of LV10051B publication Critical patent/LV10051B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of El Displays (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Amplifiers (AREA)
LVP-92-174A 1986-10-31 1992-10-27 Method for producing of lyophilized yphosphamide LV10051B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3637089 1986-10-31

Publications (2)

Publication Number Publication Date
LV10051A LV10051A (lv) 1994-05-10
LV10051B true LV10051B (en) 1995-06-20

Family

ID=6312873

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-92-174A LV10051B (en) 1986-10-31 1992-10-27 Method for producing of lyophilized yphosphamide

Country Status (25)

Country Link
EP (1) EP0265812B1 (no)
JP (1) JPS63159319A (no)
KR (1) KR900003491B1 (no)
AT (1) ATE55250T1 (no)
AU (1) AU598602B2 (no)
CA (1) CA1314231C (no)
DD (1) DD262582A5 (no)
DE (1) DE3764235D1 (no)
DK (1) DK169308B1 (no)
EG (1) EG18333A (no)
ES (1) ES2017982B3 (no)
FI (1) FI87140C (no)
GE (1) GEP19971025B (no)
GR (1) GR3000708T3 (no)
HU (1) HU197987B (no)
IL (1) IL84312A (no)
IN (1) IN168119B (no)
LV (1) LV10051B (no)
MX (1) MX8958A (no)
NO (1) NO873860L (no)
PT (1) PT86032B (no)
RU (1) RU1836079C (no)
UA (1) UA11075A (no)
YU (1) YU197387A (no)
ZA (1) ZA878183B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2040394T3 (es) * 1988-03-19 1993-10-16 Asta Medica Aktiengesellschaft Procedimiento para preparar un material liofilizado de ifosfamida y mesna.
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
KR20010034552A (ko) * 1998-03-03 2001-04-25 요시히코 시오노 포스포리파제 저해제인 소듐[[3-(2-아미노-1,2-디옥소에틸)-2-에틸-1-(페닐메틸)-1ｈ-인돌-4-일]옥시]아세테이트를 포함하는 약학적 조성물
NZ538584A (en) * 2002-09-05 2007-05-31 Bharat Serums & Vaccines Ltd Stable liquid composition of oxazaphosphorine, mesna and etherified beta-cyclodextrin
EP1569663B1 (en) * 2002-12-02 2010-04-28 Bharat Serums & Vaccines Ltd. Ifosfamide compositions for parenteral administration and a process for their preparation
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP2412359A1 (en) * 2006-09-29 2012-02-01 Infa S.A. Packaging system for pharmaceutical compositions and kit for intravenous administration
CN105900385B (zh) * 2014-12-04 2019-08-27 华为技术有限公司 在数据通信网中的负载分配

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
DE2750207A1 (de) * 1977-05-09 1978-11-16 Walton J Smith Gefriergetrocknete zusammensetzungen, insbesondere gefriergetrocknete pharmazeutische praeparate und verfahren zu deren herstellung
DE3279834D1 (en) * 1981-12-31 1989-08-31 Asta Pharma Ag 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide

Also Published As

Publication number Publication date
GR3000708T3 (en) 1991-10-10
UA11075A (uk) 1996-12-25
JPH0543684B2 (no) 1993-07-02
AU8052987A (en) 1988-05-05
ES2017982B3 (es) 1991-03-16
IL84312A (en) 1991-11-21
IL84312A0 (en) 1988-03-31
DK169308B1 (da) 1994-10-10
FI874727A (fi) 1988-05-01
LV10051A (lv) 1994-05-10
DK569687D0 (da) 1987-10-30
YU197387A (en) 1988-12-31
DK569687A (da) 1988-05-01
ZA878183B (en) 1988-05-02
EP0265812A1 (de) 1988-05-04
HU197987B (en) 1989-07-28
DE3764235D1 (de) 1990-09-13
DD262582A5 (de) 1988-12-07
GEP19971025B (en) 1997-04-06
ATE55250T1 (de) 1990-08-15
AU598602B2 (en) 1990-06-28
KR900003491B1 (ko) 1990-05-21
RU1836079C (ru) 1993-08-23
PT86032B (pt) 1990-08-31
FI87140B (fi) 1992-08-31
NO873860D0 (no) 1987-09-15
PT86032A (de) 1987-11-01
FI874727A0 (fi) 1987-10-27
NO873860L (no) 1988-05-02
HUT44932A (en) 1988-05-30
KR880004814A (ko) 1988-06-27
EP0265812B1 (de) 1990-08-08
CA1314231C (en) 1993-03-09
EG18333A (en) 1993-12-30
JPS63159319A (ja) 1988-07-02
MX8958A (es) 1993-12-01
FI87140C (fi) 1992-12-10
IN168119B (no) 1991-02-09

Similar Documents

Publication Publication Date Title
DE69617945T2 (de) Pharmazeutische zubereitungen, auf der basis von pflanzlichen etherischen ölen für die verwendung im menschlichen oder veterinären medizinischem bereich
DE68913075T2 (de) Stabilisiertes Arzneimittel und Verfahren zu dessen Herstellung.
LV10051B (en) Method for producing of lyophilized yphosphamide
DE3407823A1 (de) Lipopolysaccharid und verfahren zu seiner herstellung
DD146893A1 (de) Verfahren zur herstellung von cyclodextrin-kamillen-inklusionskomplexen
DE3638124C2 (de) Neue pharmazeutische Verwendung von Ebselen
DE1767163C3 (de) Blutdrucksenkendes Arzneimittel
DE2947646C2 (de) Substanz mit Interferon induzierender Aktivität, Verfahren zu ihrer Herstellung und ihre Verwendung
DE102007057231A1 (de) Verwendung eines potenten Produktes, extrahiert aus Wurzelstöcken von Zingiber officinale zur Behandlung einer Krankheit, die mit Helicobacter pylori in Verbindung steht
DE2009342C3 (de) Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
DE3873210T2 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.
DE10394354T5 (de) Pfanzliche Formulierung, die Centella Asiatica und Sesamum Indicum enthält, als Gehirn-Tonikum
Brändle Bedeutung der kolonialen Komponenten für die Bildung und Differenzierung der Medusen vonPodocoryne carnea M. Sars
Köllner et al. Psychotherapeutische Interventionen vor und nach Organtransplantation
DE2911332A1 (de) Antikomplementaere mittel, verfahren zu deren herstellung und arzneimittel, welche diese enthalten
CH640244A5 (en) Biologically active substance
Gedek et al. Rachitis bei Mastgeflügel durch Kontamination des Futters mit Fusarium moniliforme Sheldon: 1. Mitteilung: Feldbeobachtungen, Reproduktion des Krankheitsbildes und Behandlungsversuche
Hermann et al. Schlafstörungen
Schäfer Zur Pathogenese der calciphylaktischen Lungenfibrose
Gründer Antipsychotika
DE2729903A1 (de) Antithrombosemittel
DE60216518T2 (de) Bioaktive hexan fraktion aus vetiveria zizanioides
Drews et al. Granzen der Chemotherapie
DE1767565A1 (de) Neue Antibiotika und Verfahren zu ihrer Herstellung,Isolierung und Reinigung
DE3043291A1 (de) Vakzine gegen keuchhusten